SKYSCRAPER-07Tiragolumab and Atezolizumab for Unresectable Esophageal Squamous Cell Carcinoma Post-Chemoradiotherapy

This is a treatment study focusing on individuals with a type of esophageal cancer called squamous cell carcinoma that cannot be removed by surgery, or those who are unable or unwilling to undergo surgery. The cancer in these individuals has not worsened after undergoing a specific treatment called definitive concurrent chemoradiotherapy (dCRT). The main goal of this study is to evaluate the effectiveness and safety of using a combination of two drugs, tiragolumab and atezolizumab, compared to a placebo. This research is important as it aims to find a better treatment option for this type of cancer, potentially improving patient care and outcomes. Participants in this study are randomly assigned to one of three groups. The first group receives both tiragolumab and atezolizumab, the second group receives a placebo that matches tiragolumab and atezolizumab, and the third group receives a double placebo. The study measures the effects of these treatments by looking at how long participants live without their cancer getting worse (progression-free survival), and how long participants live overall (overall survival). These measurements help researchers understand the potential benefits and risks of the treatment.